This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.
Overall Risk Factors
HAP/ VAP Patient Profile
cIAI Patient Profile
cUTI Patient Profile
Risk factors for MDR Gram-negative infections2-6
Early adequate antibacterial therapy is crucial for patients with serious Gram-negative infections8,9
Footnotes:
**Early treatment must consider patient risk factors as well as local epidemiology.8
*30-day mortality rate among patients with P. aeruginosa bacteraemia who received delayed effective antimicrobial therapy’.10
†30-day mortality among 909 patients with BSIs caused by ESBL-producing K. pneumoniae (n=222) and E. coli (n=687). 11
ⱡ28-day mortality among 205 patients with BSIs caused by carbapenemase-producing K. pneumoniae (KPC and/or VIM). 12
§30-day mortality among 40 patients with BSIs caused by OXA-48 -producing Enterobacteriaceae.13
IIOverall mortality among 53 patients with BSIs caused by KPC-producing K. pneumoniae.14
Abbreviations:
cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; K. pneumoniae, Klebsiella pneumoniae; MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; P. aeruginosa, Pseudomonas aeruginosa; CrCl, creatinine clearance; AMR, Antimicrobial Resistance; CVC central venous catheter; ICU intensive care unit. AE, adverse event; CE, clinically evaluable; CI, confidence interval; cMITT, clinically modified intention-to-treat; TOC, test of cure;
Prescribing information
Click here for Zavicefta® (ceftazidime and avibactam) Prescribing Information
Click here for Meronem® (meropenem trihydrate) Prescribing Information
References
“It is critical for clinicians to identify patients at risk of multi-drug resistance from the onset of infection”18
*The example described here is not an actual patient, but rather a fictitious representation of a scenario for which ZAVICEFTA could be considered.
| Patient History: |
|
|---|---|
| Symptoms (developed after 4 days in hospital following fall at home): |
|
| Diagnosis: |
|
| Suspected Pathogens: |
|
Abbreviations
cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; K. pneumoniae, Klebsiella pneumoniae; MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; P. aeruginosa, Pseudomonas aeruginosa; CrCl, creatinine clearance; AMR, Antimicrobial Resistance; CVC central venous catheter; ICU intensive care unit. AE, adverse event; CE, clinically evaluable; CI, confidence interval; cMITT, clinically modified intention-to-treat; TOC, test of cure;
Prescribing information
Click here for Zavicefta® (ceftazidime and avibactam) Prescribing Information
Click here for Meronem® (meropenem trihydrate) Prescribing Information
References
“...appropriate antimicrobial therapy dictated by patient and infection risk factors…is a cornerstone in the management of intra-abdominal infections”
Sartelli M, et al. (2017)19
*The example described here is not an actual patient, but rather a fictitious representation of a scenario for which ZAVICEFTA could be considered Sartelli M, et al. (2017)19
| Patient History: |
|
|---|---|
| Symptoms: |
|
| Diagnosis: |
|
| Suspected Pathogens: |
|
Abbreviations
cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; K. pneumoniae, Klebsiella pneumoniae; MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; P. aeruginosa, Pseudomonas aeruginosa; CrCl, creatinine clearance; AMR, Antimicrobial Resistance; CVC central venous catheter; ICU intensive care unit. AE, adverse event; CE, clinically evaluable; CI, confidence interval; cMITT, clinically modified intention-to-treat; TOC, test of cure;
Prescribing information
Click here for Zavicefta® (ceftazidime and avibactam) Prescribing Information
Click here for Meronem® (meropenem trihydrate) Prescribing Information
References
"In the face of increasing rates of antimicrobial resistance in complicated urinary tract infections (cUTIs), clinicians need to understand cross-resistance patterns among commonly encountered pathogens." Zilberberg M D, et al (2020)24
*The example described here is not an actual patient, but rather a fictitious representation of a scenario for which ZAVICEFTA could be considered.
| Patient History: |
|
| Symptoms: |
|
| Diagnosis: |
|
| Suspected Pathogens: |
|
Abbreviations
cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; K. pneumoniae, Klebsiella pneumoniae; MBL, metallo-β-lactamase; OXA, oxacillinase; ESBL, extended-spectrum β-lactamase; P. aeruginosa, Pseudomonas aeruginosa; CrCl, creatinine clearance; AMR, Antimicrobial Resistance; CVC central venous catheter; ICU intensive care unit. AE, adverse event; CE, clinically evaluable; CI, confidence interval; cMITT, clinically modified intention-to-treat; TOC, test of cure;
Prescribing information
Click here for Zavicefta® (ceftazidime and avibactam) Prescribing Information
Click here for Meronem® (meropenem trihydrate) Prescribing Information
References
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021